Novartis Extends Antibody Deal With MorphoSys by Four Years | GenomeWeb

NEW YORK, June 26 (GenomeWeb News) - MorphoSys has expanded its existing therapeutic antibody collaboration with Novartis, and "in light" of the expansion" plans to update its financial guidance for 2006, the company said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.